This effect is observed in MLL-rearranged, NPM1-mutated, and a diverse array of other AML subtypes (as well as other malignancies), highlighting a role for BET proteins as terminal effectors mediating transcriptional dysregulation in cancer. The gene discussed is KMT2A; the disease is acute myeloid leukemia.